Skip to content

Direct current neuromodulation and its benefits in different populations

Transcranial direct current stimulation and the potential therapeutic approach in different populations

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-24tf9n
Enrollment
Unknown
Registered
2018-06-15
Start date
2017-06-10
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Neuropathie

Interventions

This study uses a transcranial direct current stimulation (tDCS) through a pair of 35cm2 sponge electrodes embedded with saline solution. A total of 20 patients were divided in active tDCS (10) and sh
Device
E02.331.750

Sponsors

Universidade Federal do Rio Grande do Norte
Lead Sponsor
Universidade Federal do Rio Grande do Norte
Collaborator

Eligibility

Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Participants were selected from a specialized outpatient service and regarded as suitable to participate in this study if they fulfilled the following criteria: clinical diagnoses of diabetic polyneuropathy; aged from 18 to 60 years; not lactating; no history of brain surgery, tumor, or intracranial metal implantation

Exclusion criteria

Exclusion criteria: Participants with any uncontrolled clinical disease, such as thyroid disease, cardiovascular, pulmonary, haematological or renal disease; alcohol or other substance abuse; pregnancy; lactation; neuropsychiatric disorders; history of epilepsy and metallic implants in the head were excluded. Patients with significant cognitive dysfunction were excluded. Patients were carefully evaluated by a physician

Design outcomes

Primary

MeasureTime frame
Improvement in quality of life in the active M1 group, evaluated through the SF-36 questionnaire, by increasing the score of this questionnaire;Functionality improvement in active M1 group, verified through the SF-36 questionnaire, by increasing the score of this questionnaire

Secondary

MeasureTime frame
Pain improvement in active M1 group, verified through the pain scale in the SF-36 questionnaire, from the verification of a 3 point decrease in the pain scale for a favorable clinical outcome

Countries

Brazil

Contacts

Public ContactRodrigo Freitas

Universidade federal do rio grande do norte

rodrigopegado@gmail.com+55-084-999150043

Outcome results

None listed

Source: REBEC (via WHO ICTRP)